Axon Enterprise logo
Axon Enterprise AXON
$ 612.83 0.02%
report update icon

Quarterly report 2026-Q1
added 05-16-2026

Axon Enterprise Income Statement 2025-2008 | AXON

Brief overview of profit and loss at Axon Enterprise

The comparison covers a five-year financial horizon. According to figures from Axon Enterprise, revenue changed from 681 million dollars to 2.8 billion dollars over five years. Overall revenue changed by +308.2%, equal to an annualized rate of about 32.5%. This pace points to rapid expansion of the business.

Gross profit changed from $416 million to $1.7 billion (+298.3%). Direct costs outpaced revenue, limiting the benefit of changes in sales. The gross margin was 61.1% at the start and 59.7% at the end. There was no meaningful shift in gross profitability.

Over the period, EBITDA shifted from −1.7 million dollars to 21.1 million dollars, a change of +1358.8%. Operating profitability strengthened faster than the scale of sales. EBITDA margin was −0.2% at the start and 0.8% at the end. EBITDA as a share of revenue remained steady.

Across the five years, the net result shifted from −$1.7 million to $125 million. The company restored profitability by the end of the period.

Market value was $10.2 billion at the start and $30.6 billion at the end. Capitalization grew more slowly than the underlying results.

Summary assessment

The financial profile remains mixed, with strengths and risks moving in different directions. The constructive conclusion rests on positive operating leverage, revenue expansion and a stronger final result. Caution is warranted because of limited operating profitability and pressure from direct costs. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Axon Enterprise

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

30.6 B 39.8 B 20.2 B 14.2 B 9.28 B 10.2 B 4.64 B 2.8 B - - 824 M 1.43 B 846 M 449 M 278 M 258 M 282 M -

Shares

78.1 M 75.7 M 74.2 M 71.1 M 66.2 M 61.8 M 59.2 M 56.4 M - - 53.5 M 52.9 M 51.9 M 53.8 M 59.4 M 62.5 M 61.9 M -

Historical Prices

392 526 272 200 140 165 77.4 53.8 34.8 25.7 19.4 23.5 19.2 7.47 4.03 4.13 4.56 7.06

Net Income

125 M 377 M 176 M 147 M -60 M -1.72 M 882 K 29.2 M 5.21 M 17.3 M 19.9 M 19.9 M 18.2 M 14.7 M -7.04 M -4.38 M -1.11 K -

Revenue

2.78 B 2.08 B 1.56 B 1.19 B 863 M 681 M 531 M 420 M 344 M 268 M 198 M 165 M 138 M 115 M 90 M - - -

Cost of Revenue

1.12 B 841 M 605 M 461 M 322 M 265 M 224 M 161 M 137 M 97.7 M 69.2 M 63 M 52 M 47 M 41.8 M - - -

Gross Profit

1.66 B 1.24 B 955 M 726 M 541 M 416 M 307 M 259 M 207 M 171 M 129 M 102 M 85.8 M 67.7 M 44.5 M 45.4 M 63.4 M -

Operating Income

-62.1 M 58.5 M 157 M 93 M -168 M -14.2 M -6.39 M 24.8 M 13 M 31.9 M 35.3 M 32.5 M 27.9 M 22.5 M -10.9 M -5.14 M -79.2 K -

Interest Expense

99.9 M 286 M -41.9 M 99 M 25.3 M - - - - - - - - - - - - -

EBITDA

21.1 M 107 M 176 M 116 M -149 M -1.68 M -655 K 30.9 M 21.1 M 35.5 M 37.2 M 33.8 M 30.6 M 27 M 1.33 M 2.15 M 3.56 M -

Operating Expenses

1.72 B 1.18 B 799 M 633 M 709 M 430 M 314 M 234 M 194 M 139 M 93.3 M 69 M 56.5 M 47.2 M 51.3 M 50.5 M 63.5 M -

General and Administrative Expenses

1.04 B 741 M 495 M 399 M 515 M 307 M 178 M 131 M 121 M 92.9 M 57.1 M 44.8 M 39.3 M - 41.3 M 39 M 43.5 M -

All numbers in USD currency

Quarterly Income Statement Axon Enterprise

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

80.2 M 78.4 M 78 M 76.9 M 76.6 M 75.7 M 75.5 M 75.4 M 74.8 M 74.2 M 72.6 M 71.5 M 71.1 M 71 M 71 M 70.9 M 66.2 M 65.2 M 64 M 63.8 M 63.5 M 60.3 M 59.6 M 59.5 M 59.3 M 59.2 M 58.9 M 58.8 M 58.3 M 55.5 M 53.1 M 53 M 52.8 M 52.7 M 52.4 M 52.3 M 52.2 M 52.5 M 53.7 M 53.7 M 53.7 M 53.6 M 53.2 M 53 M 52.5 M 53.4 M 53.2 M 52.7 M 51.3 M 51.1 M 52.7 M 52.8 M 52.5 M 54.5 M 55.7 M 55.7 M 58.8 M 60.6 M 62.4 M

Net Income

169 M -2.19 M 36.1 M 88 M - 67 M 40.8 M 133 M 59.4 M 12.4 M 45.1 M - 12.1 M 51 M 54.9 M - 48.5 M -47.1 M -47.9 M - -873 K -30.8 M 4.07 M -12.4 M 6.1 M 738 K 6.42 M 2.08 M 5.71 M 8.48 M 12.9 M 5.21 M 422 K 2.28 M 4.58 M 6.34 M 3.84 M 3.65 M 3.46 M 5.1 M 1.52 M 6.1 M 7.2 M 5.09 M 7.56 M 3.88 M 3.39 M 5.38 M 5.11 M 4.46 M 3.3 M 3.82 M 3.68 M 3.44 M 3.8 M -5.9 M 1.14 M -2.29 M 19.7 K

Revenue

807 M 711 M 669 M 604 M - 544 M 504 M 460 M 414 M 375 M 343 M - 312 M 286 M 256 M - 232 M 219 M 195 M - 166 M 141 M 147 M 172 M 131 M 112 M 116 M 115 M 105 M 99.2 M 101 M 94.7 M 90.3 M 79.6 M 79.2 M 82.1 M 71.9 M 58.8 M 55.5 M - 50.4 M 46.7 M 44.8 M - 44.3 M 37.2 M 36.2 M - 35.2 M 32.2 M 30.4 M - 28.8 M 28.2 M 25.6 M - 24.4 M 21.2 M -

Cost of Revenue

330 M 283 M 265 M 238 M - 214 M 200 M 201 M 158 M 142 M 139 M - 118 M 112 M 101 M - 87.4 M 80.9 M 71.7 M - 68.2 M 53.1 M 58.6 M - 50.7 M 46.8 M 46.9 M - 39.2 M 36.1 M 36.8 M - 40.5 M 34 M 30.6 M - 25.3 M 21.5 M 18.6 M - 19.3 M 16 M 14.9 M - 15.6 M 14 M 14 M - 13.1 M 12.4 M 12 M - 12 M 11.7 M 10.4 M - - - -

Gross Profit

477 M 427 M 404 M 366 M - 331 M 304 M 259 M 255 M 232 M 204 M - 193 M 174 M 156 M - 145 M 138 M 123 M - 98.2 M 88.2 M 88.6 M 92.6 M 80.2 M 65.6 M 68.9 M 65.3 M 65.6 M 63.1 M 64.5 M 63 M 49.8 M 45.6 M 48.7 M 49.8 M 46.6 M 37.3 M 36.9 M 37 M 31.1 M 30.7 M 29.9 M 27.4 M 28.7 M 23.2 M 22.2 M 25.6 M 22.1 M 19.7 M 18.5 M 19.2 M 16.8 M 16.5 M 15.2 M 6.98 M 13.1 M 12.2 M 12.2 M

Operating Income

29.2 M -2.13 M -1.04 M -8.79 M - 24.1 M 32.9 M 16.5 M 55.1 M 40.3 M 16.6 M - 32.1 M 21.4 M 17.2 M - 2.89 M -93.7 M -50.3 M - -5.45 M -13.7 M -800 K - 6.62 M -1.3 M 2.67 M - 3.97 M 5.3 M 13.6 M - -799 K 824 K 5.35 M - 11.1 M 6.21 M 5.14 M - 6.71 M 9.37 M 10.7 M - 12.5 M 6.21 M 4.86 M - 6.88 M 6.81 M 5.26 M - 5.28 M 6.06 M 6.46 M - 1.21 M -5.02 M 110 K

Interest Expense

189 M 22.8 M -32.4 M 114 M - 44.5 M 7.93 M 139 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

59.6 M 54.1 M 35.6 M 10.7 M - 54.8 M 57.4 M 23.8 M - - 23.3 M - 32.1 M 33.4 M 22.9 M - 2.89 M -85.1 M -46 M - 3.5 M -7.86 M 2.08 M - 14.8 M 4.19 M 5.47 M - 12.2 M 10.5 M 16 M - 1.48 M 2.62 M 6.95 M - 12 M 7.15 M 6.04 M - 7.65 M 10.1 M 11.4 M - 13.6 M 7.32 M 6.02 M - 7.97 M 8.34 M 6.68 M - 7 M 7.79 M 8.12 M - 3.21 M -2.82 M 2.18 M

Operating Expenses

448 M 429 M 405 M 375 M - 307 M 271 M 242 M 200 M 192 M 187 M - 161 M 153 M 139 M - 142 M 232 M 174 M - 104 M 102 M 89.4 M - 73.6 M 66.9 M 66.2 M - 61.7 M 57.8 M 50.9 M - 50.6 M 44.8 M 43.3 M - 35.5 M 31.1 M 31.8 M - 24.4 M 21.3 M 19.1 M - 16.2 M 17 M 17.4 M - - - - - - - - - - - -

General and Administrative Expenses

259 M 253 M 242 M 224 M - 192 M 169 M 151 M 123 M 120 M 117 M - 102 M 95 M 90.1 M - 99.3 M 178 M 127 M - 74.4 M 72.3 M 63 M - 48.4 M 43.4 M 42.9 M - 39.7 M 39.3 M 35.8 M - 36.4 M 31.8 M 30.9 M - 28.1 M 24.4 M 24.8 M - 17.8 M 15.4 M 14.6 M - 12.4 M 13.5 M 13.7 M - 12.8 M 10.9 M 11.2 M - 9.54 M 8.4 M 8.85 M - 9.48 M 9.07 M 9.35 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Axon Enterprise (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada